Intravenous immunoglobulin (IVIG)(Sanofi)은 Kawasaki Disease 표적 치료제로, Kawasaki Disease 영역에서 개발·상용화 중입니다. 작용기전: targeting immune checkpoints - regulatory pathway. Phase 2에서 효능·안전성 신호를 검증 중입니다. PFS: 1. 차별점: unique case of a patient who was successfully treated for IM3OS and highlights the potential use of flow cytometry to provide.
Kawasaki Disease
Kawasaki Disease
Recruiting
unique case of a patient who was successfully treated for IM3OS and highlights the potential use of flow cytometry to provide
targeting immune checkpoints - regulatory pathway
immune-mediated subtypes remain inconclusive and warrant further research with biologically stratified, adequately powered trials
Biomarker analysis identified a higher abundance of Eubacterium, Bacteroides, Escherichia-Shigella, and Actin
resistance to intravenous immunoglobulin (IVIG) remains a significant clinical challenge
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Intravenous immunoglobulin (IVIG)(Sanofi)은 Kawasaki Disease 표적 치료제로, Kawasaki Disease 영역에서 개발·상용화 중입니다. 작용기전: targeting immune checkpoints - regulatory pathway. Phase 2에서 효능·안전성 신호를 검증 중입니다. PFS: 1. 차별점: unique case of a patient who was successfully treated for IM3OS and highlights the potential use of flow cytometry to provide.
Kawasaki Disease
Kawasaki Disease
Recruiting
unique case of a patient who was successfully treated for IM3OS and highlights the potential use of flow cytometry to provide
targeting immune checkpoints - regulatory pathway
immune-mediated subtypes remain inconclusive and warrant further research with biologically stratified, adequately powered trials
Biomarker analysis identified a higher abundance of Eubacterium, Bacteroides, Escherichia-Shigella, and Actin
resistance to intravenous immunoglobulin (IVIG) remains a significant clinical challenge
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.